UNSPSC 51333200: Antipsychotic nitrogen mustard compounds

Antipsychotic drugs made from A group of alkylating agents derived from mustard gas, with the sulfur replaced by nitrogen. They were formerly used as toxicants and vesicants, but now function as antineoplastic agents. These compounds are also powerful mutagens, teratogens, immunosuppressants, and carcinogens.

UNSPSC 51333200 Antipsychotic nitrogen mustard compounds, a Class code, shows limited alignment with current state and local procurement activity. The single recent opportunity on record — Seminole County, Florida's IFB 60459723LAS — solicits naloxone and safe drug deactivation systems, not antipsychotic compounds. Naloxone is an opioid antagonist used for overdose reversal, and drug deactivation systems are harm-reduction infrastructure; neither falls within the nominal scope of antipsychotic nitrogen mustard pharmaceuticals. The mismatch suggests either a tagging error in the source system or a fundamental divergence between the code's intended scope and how state and local procurement offices are classifying related health-care and public-safety acquisitions. No other recent opportunities under this code are reported.

Seminole County, a Florida county government, issued the only tracked solicitation under this code. The IFB was posted June 30, 2026, with a response deadline of July 26, 2023 — a date inconsistency in the source itself that obscures the true timeline. The procurement requests 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carries a two-year initial term with one-year renewal option and includes standard compliance requirements (E-Verify, drug-free workplace certification, and federal environmental regulations tied to potential FEMA funding). Vendor selection is price-based, with bidders responsible for all shipping and delivery costs. This code does not reflect active or recent state and local procurement interest in antipsychotic compounds; business development professionals tracking pharmaceutical acquisitions should monitor related family and commodity codes or focus efforts on other therapeutic categories.